GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Edesa Biotech Inc.
Edesa Biotech is a Canadian biotechnology company. Its stock price is highly volatile and driven by news of clinical trials of its drug candidates in dermatology and gastroenterology.
Share prices of companies in the market segment - Pharma immune
Edesa Biotech is a Canadian biopharmaceutical company developing drugs for the treatment of dermatological and gastrointestinal diseases. We have classified it in the Pharma: Immunology category. The chart below shows how investors value companies operating in this broad field.
Broad Market Index - GURU.Markets
Edesa Biotech is a Canadian biotech company developing drugs for the treatment of dermatological and gastrointestinal diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Edesa shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
EDSA - Daily change in the company's share price Edesa Biotech Inc.
Edesa Biotech, Inc.'s daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its dermatological drugs.
Daily change in the price of a set of shares in a market segment - Pharma immune
Edesa Biotech, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with EDSA, which focuses on dermatological and gastrointestinal diseases, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Edesa Biotech is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Edesa Biotech Inc.
Edesa Biotech, Inc.'s year-over-year performance is a story about its drug development for the treatment of inflammatory diseases. Its 12-month market capitalization is entirely dependent on clinical trial data. The success of its lead candidate, which is being studied for allergic contact dermatitis, could be a fundamental breakthrough for the company.
Annual dynamics of market capitalization of the market segment - Pharma immune
Edesa Biotech, Inc. is a clinical-stage biotech company. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs inherent in the biotech sector, compared to big pharma, whose performance is more stable.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Edesa Biotech is a biotech company whose stock performance is entirely dependent on clinical trial results. A comparison with the market clearly demonstrates that its investors are focusing not on the Fed's interest rate but on lab news. Its path is a series of binary events, each of which can dramatically increase or decrease the company's value.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Edesa Biotech Inc.
Edesa Biotech is a clinical-stage biopharmaceutical company. Its monthly performance is entirely dependent on the results of its clinical trials. News about its drugs for dermatological and respiratory diseases are binary events.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Edesa Biotech is a biopharmaceutical company developing drugs for the treatment of dermatological and gastrointestinal diseases, where inflammation predominates. The chart below shows the overall dynamics in the immunology sector, reflecting the active search for new treatments for chronic inflammatory conditions.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks often live in a world of their own, where clinical trial news trumps overall market trends. The chart below shows the pulse of the broader market. Does Edesa Biotech move in sync with it, or do its R&D developments create a completely independent story?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Edesa Biotech Inc.
Edesa Biotech, which develops drugs for dermatological and gastrointestinal diseases, is extremely volatile. Its weekly performance is a direct response to clinical trial data for its candidates, which is crucial to the future of the company, which operates in the high-risk biotech sector.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Edesa Biotech operates in the volatile biopharmaceutical sector, where investor sentiment often influences all players. M&A news or general regulatory changes can lift or derail the entire sector. The chart will show whether EDSA is moving with the industry or whether its drug development successes are creating their own story.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Edesa Biotech, Inc., as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how EDSA shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
EDSA - Market capitalization of the company Edesa Biotech Inc.
Edesa Biotech's market capitalization is another story of hope in the field of immunology. This biotech's stock price reflects investors' faith in its inflammatory disease drugs. Its volatile dynamics reflect the market's assessment of its clinical data and chances of success in this complex area of medicine.
EDSA - Share of the company's market capitalization Edesa Biotech Inc. within the market segment - Pharma immune
Edesa Biotech is a biopharmaceutical company developing drugs for the treatment of inflammatory skin and gastrointestinal diseases. Its market share is based on its pipeline of candidates. The chart shows how the market views its scientific approach and commercialization prospects.
Market capitalization of the market segment - Pharma immune
Edesa Biotech develops drugs for the treatment of dermatological and gastrointestinal diseases. The chart below shows the market capitalization of the immunology pharmaceutical sector. This represents a market that is seeking new ways to combat inflammatory processes in the body.
Market capitalization of all companies included in a broad market index - GURU.Markets
Edesa Biotech is a biopharmaceutical company developing drugs for the treatment of inflammatory and immunological diseases. Its market capitalization reflects the potential of its research and development. The chart below shows the economic weight of early-stage companies.
Book value capitalization of the company, segment and market as a whole
EDSA - Book value capitalization of the company Edesa Biotech Inc.
Edesa Biotech is built on a pipeline of developments. The company's book value consists of licenses for several inflammatory disease drug candidates and cash for their clinical trials. The chart below shows how the company manages its research capital.
EDSA - Share of the company's book capitalization Edesa Biotech Inc. within the market segment - Pharma immune
Edesa Biotech, Inc., a biopharmaceutical company, is focused on R&D. Its laboratories are its primary physical asset. The S_BCap_Seg graph shows its small share of physical infrastructure, which is typical for a company in the research stage.
Market segment balance sheet capitalization - Pharma immune
Edesa Biotech is a clinical-stage biopharmaceutical company. Its value lies in the potential of its drugs. A book value chart shows that its assets are almost entirely intangible, which is typical for an innovative company far from mass production.
Book value of all companies included in the broad market index - GURU.Markets
Edesa Biotech's assets are focused on developing drugs for the treatment of inflammation. The company's book value reflects its rights to several candidate molecules and capital for clinical trials. This material base is aimed at developing therapies for the treatment of hemorrhoids and other inflammatory diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Edesa Biotech Inc.
Edesa Biotech is a clinical-stage biopharmaceutical company. Its book value is its cash reserves. Its market capitalization is the volatile valuation of its immune-diseases drug candidates, which is dependent on clinical trial news.
Market to book capitalization ratio in a market segment - Pharma immune
Edesa Biotech is a Canadian biopharmaceutical company. Its value depends almost entirely on the success of clinical trials. The chart shows how market expectations for its drugs compare to its tangible assets, which consist primarily of cash.
Market to book capitalization ratio for the market as a whole
Edesa Biotech is a biopharmaceutical company developing drugs to treat inflammatory diseases. Its value depends almost entirely on the success of its clinical trials. The chart demonstrates how market valuation reflects investors' faith in science and future cash flows, rather than current tangible assets.
Debts of the company, segment and market as a whole
EDSA - Company debts Edesa Biotech Inc.
Edesa Biotech, a biotech company, uses debt to finance its clinical programs. This chart shows the capital raised to conduct trials of its drugs for various inflammatory diseases, including dermatological and gastrointestinal disorders.
Market segment debts - Pharma immune
Edesa Biotech is a clinical-stage biopharmaceutical company developing drugs for the treatment of inflammatory diseases. Its financial future is entirely dependent on the results of current and future clinical trials. This chart shows its cash reserves and the rate at which they are spent on R&D.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Edesa Biotech Inc.
Edesa Biotech is a biopharmaceutical company focused on immunology and dermatology. This chart shows its financial strategy. For a company in the clinical trials stage, without stable revenue, raising debt is a sign of high risk and confidence in the success of its developments, which requires careful evaluation by investors.
Market segment debt to market segment book capitalization - Pharma immune
Edesa Biotech is a biopharmaceutical company focused on immune and dermatological diseases. This chart for the biotech sector shows how the industry as a whole raises capital to fund clinical trials. It helps understand how the company's financial position is typical for an industry where the path to market is long and expensive.
Debt to book value of all companies in the market
Edesa Biotech is a biopharmaceutical company developing drugs for the treatment of dermatological and gastrointestinal diseases. This chart, showing the debt-to-book value ratio, is important for assessing the investment climate in biotech. The market's willingness to finance companies with long development cycles determines Edesa's ability to raise capital.
P/E of the company, segment and market as a whole
P/E - Edesa Biotech Inc.
Edesa Biotech is a biopharmaceutical company developing drugs for the treatment of dermatological and gastrointestinal diseases. This chart reflects its belief in its scientific research. The indicator's performance depends on clinical trial results. Success could unlock access to major markets and lead to significant growth in the company's value.
P/E of the market segment - Pharma immune
Edesa Biotech, Inc. is a biotech company. This chart shows the average P/E ratio for the biotech sector. Comparing a company's P/E to this benchmark allows one to understand how highly the market values its development pipeline compared to the average prospects of other biotech companies.
P/E of the market as a whole
Edesa Biotech is a biopharmaceutical company developing drugs for the treatment of dermatological and gastrointestinal diseases. This chart shows the sentiment in the biotech sector. The company's valuation depends on the results of its clinical trials and whether it can bring its developments to market in competitive therapeutic areas.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Edesa Biotech Inc.
Edesa Biotech is a clinical-stage biopharmaceutical company developing drugs for the treatment of dermatological and gastrointestinal diseases. The graph reflects speculative revenue expectations, which are entirely dependent on the success of clinical trials.
%20P%2FE%20Edesa%20Biotech%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Edesa-Biotech-Inc.&v=1772604051785 "Chart of the company's future (projected) P/E Edesa Biotech Inc.")
Future (projected) P/E of the market segment - Pharma immune
Edesa Biotech is a clinical-stage company developing drugs for the treatment of inflammatory and immunological diseases. This chart shows its future profitability expectations, allowing us to assess how the market perceives its scientific developments and potential for new treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772604051861 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Edesa Biotech is a Canadian clinical-stage biotech company developing drugs for the treatment of inflammatory diseases. Its value is based on the expected future success of its drug candidates. It is completely unrelated to general market forecasts, but depends on scientific data.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772604051885 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Edesa Biotech Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of dermatological and gastrointestinal diseases with inflammatory components. Its financial indicators reflect clinical trial expenses. This chart shows the investment in the development of new therapeutic agents.
Profit of companies in the market segment - Pharma immune
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of dermatological and gastrointestinal diseases. This chart shows the profitability of the immunology segment. R&D costs impact current overall profitability, but its drug candidates have the potential to offer new treatments for common diseases.
Overall market profit
Edesa Biotech is a clinical-stage biopharmaceutical company developing drugs for the treatment of dermatological and gastrointestinal diseases. Its future depends on the success of clinical trials. This chart illustrates general economic cycles, while Edesa Biotech works to develop innovative treatments that address specific medical problems.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Edesa Biotech Inc.
Edesa Biotech is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of dermatological and gastrointestinal diseases. The forecast for future profits reflected here is long-term and contingent on the successful completion of clinical trials. It demonstrates the analysts' confidence in the scientific potential of the company's development pipeline.
%20profit%20of%20the%20company%20Edesa%20Biotech%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Edesa-Biotech-Inc.&v=1772604052154 "Graph of future (projected) profit of the company Edesa Biotech Inc.")
Future (predicted) profit of companies in the market segment - Pharma immune
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of dermatological and gastrointestinal diseases. This chart shows revenue projections for the immunology pharmaceutical segment. It reflects expectations for new treatments for inflammatory diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772604052156 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Edesa Biotech is a biopharmaceutical company. As with any biotech company in development, access to capital is critical for Edesa. The overall market return forecast influences investors' willingness to finance risky projects. The chart below shows how favorable the current investment climate is for raising funds.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772604052188 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Edesa Biotech Inc.
Edesa Biotech is a clinical-stage biopharmaceutical company developing drugs for the treatment of inflammatory diseases. The company does not have stable revenue. P/S will become important after the product launch to assess the market acceptance of its therapy.
P/S market segment - Pharma immune
Edesa Biotech is a clinical-stage biopharmaceutical company developing drugs for the treatment of dermatological and gastrointestinal diseases with inflammatory components. This chart shows how the market evaluates the scientific potential of their candidates and future revenue streams in the event of successful clinical trials and regulatory approval.
P/S of the market as a whole
Edesa Biotech is a biotech company with a pipeline of developments in dermatological and gastrointestinal diseases. The company has no commercial revenue. This chart, based on actual revenue, highlights that Edesa's valuation is a bet on the success of its clinical programs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Edesa Biotech Inc.
Edesa Biotech is a biopharmaceutical company developing drugs for the treatment of dermatological and gastrointestinal diseases. This chart reflects investor expectations for future revenue from its developments, which depend on the results of clinical trials and the potential of its drugs in relevant medical markets.
%20P%2FS%20Edesa%20Biotech%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Edesa-Biotech-Inc.&v=1772604052517 "The graph of the company's future (projected) P/S Edesa Biotech Inc.")
Future (projected) P/S of the market segment - Pharma immune
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for dermatological and gastrointestinal diseases. This chart shows how the market assesses the future commercial potential of its drug candidates. It compares it to other immunology companies, reflecting its niche developments.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772604052572 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Edesa Biotech is a biopharmaceutical company developing drugs for the treatment of dermatological and gastrointestinal diseases. Its portfolio is aimed at addressing unmet medical needs. This chart illustrates general revenue expectations, and EDSA shows how biotech companies are finding their niches in the vast pharmaceutical market.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772604052689 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Edesa Biotech Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of dermatological and gastrointestinal diseases. Because its products are in development, the company has no sales revenue. Any revenue reflected in this chart likely comes from payments under partnership agreements.
Sales of companies in the market segment - Pharma immune
Edesa Biotech is a clinical-stage biopharmaceutical company. At this stage, it likely has no revenue from product sales. The graph may reflect revenue from licensing agreements or grants, which are a key source of funding for its research and development.
Overall market sales
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company. Its value and prospects depend solely on the results of its clinical trials. This overall market performance chart has absolutely no bearing on Edesa's valuation, as its mission is focused on science and the development of new treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Edesa Biotech Inc.
Edesa Biotech is a clinical-stage biopharmaceutical company developing drugs for the treatment of inflammatory diseases. Its revenue forecast is entirely dependent on clinical trial success. This chart reflects analysts' speculative expectations for the commercial potential of its pipeline.
%20sales%20of%20the%20company%20Edesa%20Biotech%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Edesa-Biotech-Inc.&v=1772604052929 "Schedule of future (projected) sales of the company Edesa Biotech Inc.")
Future (projected) sales of companies in the market segment - Pharma immune
Edesa Biotech is a biopharmaceutical company developing drugs for the treatment of dermatological and gastrointestinal diseases. This chart shows projected revenue for the entire immunology segment. It allows one to estimate the potential demand for new treatments, which is key to the commercialization of Edesa's development pipeline.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772604052955 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Edesa Biotech is a clinical-stage biopharmaceutical company developing drugs for the treatment of dermatological and gastrointestinal diseases. Its value is determined by the potential of its scientific developments. This chart of overall market expectations reflects investor risk appetite, which is critical for funding long-term biotech projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772604053122 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Edesa Biotech Inc.
Edesa Biotech is a clinical-stage biopharmaceutical company developing drugs for the treatment of dermatological and gastrointestinal diseases. This chart reflects its current focus on research. It does not show profit, but rather the efficiency of capital management for clinical trials.
Market segment marginality - Pharma immune
Edesa Biotech is a biopharmaceutical company developing innovative treatments for dermatological and gastrointestinal diseases with inflammatory components. This chart shows the average profit margin in the immunology sector. It serves as a benchmark for assessing the potential commercial value of Edesa's drugs if they successfully complete clinical trials.
Market marginality as a whole
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company. Its future depends on the results of its research. This graph of average market returns has nothing to do with the binary logic of biotech, where one successful drug can create enormous value, while a failed trial can wipe it out.
Employees in the company, segment and market as a whole
Number of employees in the company Edesa Biotech Inc.
Edesa Biotech is a clinical-stage biopharmaceutical company developing drugs for the treatment of inflammatory diseases. Its small team of scientists and clinicians manages several research programs. This graph illustrates the size of its compact yet efficient R&D organization.
Share of the company's employees Edesa Biotech Inc. within the market segment - Pharma immune
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for dermatological and gastrointestinal diseases. This chart illustrates its scientific focus. It reflects the proportion of dermatologists, gastroenterologists, and researchers working on developing new drugs for the treatment of inflammatory diseases that Edesa brings together.
Number of employees in the market segment - Pharma immune
Edesa Biotech, Inc. is a biopharmaceutical company developing drugs for the treatment of dermatological and gastrointestinal diseases. This chart shows employment in the immunology sector. The growing number of specialists in this field reflects progress in the treatment of inflammatory diseases and the search for new targeted therapies.
Number of employees in the market as a whole
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on immunological diseases. Developing new drugs is a long and complex process that requires highly skilled professionals. This chart reflects the overall employment where the biotech sector contributes to the innovation economy.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Edesa Biotech Inc. (EDSA)
Edesa Biotech is an immunology company. Its value is determined by the potential of its scientific developments. This chart shows the enormous market premium for research in one of the hottest areas of medicine. The high market capitalization per employee reflects the intellectual capital of its research team.
%20of%20the%20company%20Edesa%20Biotech%20Inc.%20(EDSA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Edesa-Biotech-Inc.-EDSA&v=1772604053770 "Chart of market capitalization per employee (in thousands of dollars) of the company Edesa Biotech Inc. (EDSA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Edesa Biotech is a biopharmaceutical company developing drugs for the treatment of inflammatory diseases. Its market capitalization per employee reflects the market valuation of its research portfolio. This high figure, compared to other sectors, indicates the significant potential of its developments should clinical trials be successful.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772604053849 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Edesa Biotech is a clinical-stage biopharmaceutical company developing drugs for the treatment of dermatological and gastrointestinal diseases. Its value is determined by its scientific potential. This chart reflects how investors assess the prospects of its clinical programs and the team's ability to bring them to success.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772604053879 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Edesa Biotech Inc. (EDSA)
Edesa Biotech is a clinical-stage biotech company developing drugs for the treatment of inflammatory diseases (e.g., dermatitis). The company has no commercial products. This negative graph shows how much investor capital is "burned" for each scientist working on these R&D programs.
%20Chart%20Edesa%20Biotech%20Inc.%20(EDSA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Edesa-Biotech-Inc.-EDSA&v=1772604054010 "Company Profit Per Employee (in thousands of dollars) Chart Edesa Biotech Inc. (EDSA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of dermatological and gastrointestinal diseases. This chart reflects the potential value of their developments. It shows the high profit potential of a successful drug developed by a small team of scientists to treat common diseases with unmet needs.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772604054096 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing treatments for dermatological and gastrointestinal diseases. Like other R&D biotech companies, this chart reflects cost intensity. It shows how much the company invests in each employee to advance its drugs through clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772604054132 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Edesa Biotech Inc. (EDSA)
Edesa Biotech is a clinical-stage biopharmaceutical company. This graph, showing zero revenue per employee, is typical for the industry. It illustrates a period when all resources are focused on research. Future drug success will lead to explosive growth in this metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Edesa-Biotech-Inc.-EDSA&v=1772604054186 "Sales chart per company employee Edesa Biotech Inc. (EDSA)")
Sales per employee in the market segment - Pharma immune
Edesa Biotech (EDSA) is a Canadian biopharmaceutical company developing treatments for dermatological and gastrointestinal inflammatory diseases. This chart shows the average revenue per employee in the pharmaceutical segment. For Edesa, which is in the R&D stage, comparing it to this benchmark (zero) highlights their focus on science rather than current sales.
Sales per employee for the market as a whole
Edesa Biotech (EDSA) is a clinical-stage biotech company. It has no revenue. This metric is irrelevant. The company's entire value lies in the potential of its R&D portfolio and the success of its clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Edesa Biotech Inc. (EDSA)
Edesa Biotech is a clinical-stage biotech company specializing in the treatment of inflammatory skin diseases (dermatitis). This chart shows the odds on the failure of their key drug. The bears believe their candidate will fail to prove its efficacy in trials, and the company, with no revenue, will run out of money.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Edesa-Biotech-Inc.-EDSA&v=1772604054353 "Short Shares Chart for the Company Edesa Biotech Inc. (EDSA)")
Shares shorted by market segment - Pharma immune
Edesa Biotech (EDSA) is a biotech with a broad portfolio, developing treatments ranging from dermatitis to Crohn's disease. This chart highlights the pessimism in the sector. The growing short position in the sector is a bet against the "biotech orchestra." Investors doubt EDSA has the capital and focus to complete any of its many risky projects and expect them to fail.
Shares shorted by the overall market
Edesa (EDSA) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing EDSA won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Edesa Biotech Inc. (EDSA)
Edesa Biotech is a biotech company specializing in the treatment of inflammatory diseases. Like many in the sector, its "pulse" is unstable. This chart shows the classic biotech cycle: long, cold periods of R&D, followed by a sharp surge in investor interest on any positive clinical trial data.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Edesa-Biotech-Inc.-EDSA&v=1772604054447 "RSI 14 indicator chart for the company's stock Edesa Biotech Inc. (EDSA)")
RSI 14 Market Segment - Pharma immune
Edesa Biotech is a Canadian clinical-stage biotech company developing treatments for inflammatory and immunological diseases, including dermatology and gastroenterology. This chart reflects the overall sentiment in the biotech sector, helping to assess how the market views this speculative industry.
RSI 14 for the overall market
Edesa Biotech (EDSA) is a biotech R&D company. Like everyone in its sector, it's critically dependent on this schedule. Market euphoria offers the opportunity to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast EDSA (Edesa Biotech Inc.)
Edesa Biotech (EDSA) is a biotech company developing drugs for the treatment of inflammatory diseases, including dermatology and acute respiratory distress syndrome (ARDS). This chart shows the average 12-month forecast. It reflects analysts' speculative assessment of its clinical pipeline.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-EDSA-Edesa-Biotech-Inc.&v=1772604054534 "A chart showing analyst consensus forecasts for the expected stock price. EDSA (Edesa Biotech Inc.)")
The difference between the consensus estimate and the actual stock price EDSA (Edesa Biotech Inc.)
Edesa Biotech is a biotech company developing drugs to treat severe inflammatory and immune diseases. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their confidence in the company's R&D portfolio and its chances of clinical success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-EDSA-Edesa-Biotech-Inc.&v=1772604054615 "A chart showing the difference between the consensus forecast and the actual stock price. EDSA (Edesa Biotech Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Edesa Biotech is a clinical-stage biotech company developing new treatments for inflammatory and autoimmune diseases. This is a high-risk R&D venture. This chart reflects analysts' overall expectations for the immunopharmacology sector. It shows whether experts believe R&D pipelines in this complex field will be successful.
Analysts' consensus forecast for the overall market share price
Edesa Biotech is a biotech company specializing in developing drugs to treat immune-inflammatory diseases. This chart shows the overall market "risk appetite." For Edesa, a high-risk clinical-stage company, overall market optimism (as shown by the rising chart) is critical for raising the capital needed to fund long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Edesa Biotech Inc.
Edesa Biotech is a clinical-stage biotech company focused on immunology. They develop drugs for the treatment of inflammatory diseases, primarily dermatological ones (atopic dermatitis). This chart is a pure indicator of faith in their R&D. It doesn't reflect revenue, but rather a speculative estimate of their scientific progress and clinical trial data.
AKIMA Market Segment Index - Pharma immune
Edesa Biotech (EDSA) is a biopharmaceutical company developing drugs for the treatment of inflammatory and immune diseases, including dermatology (eczema) and gastroenterology. The chart shows the average index for the segment, helping investors assess how the risks and potential of Edesa's diversified portfolio compare to the sector average.
The AKIM Index for the overall market
Edesa Biotech is a biopharmaceutical company developing treatments for inflammatory and immune diseases (dermatitis, ARDS). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this clinical story compares to the overall economic trends affecting biotech.
